comparemela.com

Latest Breaking News On - European summary - Page 20 : comparemela.com

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma

Breyanzi represents a differentiated CAR T cell therapy with demonstrated rapid and durable complete responses and a manageable safety profile Approval of Breyanzi is based on results from TRANSCEND

United statesUnited kingdomSamit hirawatBristol myers squibbKimberly whitefieldBristol myers squibb companyInternational lymphoma study groupEuropean unionLymphoma research foundationAmerican cancer societyUniversity of viennaEuropean commissionDrug administrationExchange commissionMyers squibbMarketing authorization

Jyseleca® approved in Japan for ulcerative colitis

Approval of additional indication based on Phase 2b/3 SELECTION study in patients with moderate-to-severe ulcerative colitis .

Region flamandeUnited kingdomNorthern irelandGreat britainVan gijselSandra cauwenberghsMarieke vermeerschAnna gibbinsGilead sciencesGilead scienceskk tokyoExchange commissionTherapeutic area communicationsEa pharma co ltdEisai co ltdJapanese ministry of healthEuropean union

Investegate |Galapagos NV Announcements | Galapagos NV: Jyseleca® approved in Japan for ulcerative colitis

Investegate announcements from Galapagos NV, Jyseleca® approved in Japan for ulcerative colitis

Region flamandeUnited kingdomNorthern irelandGreat britainVan gijselSandra cauwenberghsMarieke vermeerschAnna gibbinsGilead sciencesGilead scienceskk tokyoExchange commissionTherapeutic area communicationsEa pharma co ltdEisai co ltdJapanese ministry of healthEuropean union

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022Data reinforce ViiV Healthcare’s leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention London, 7 February 2022 – ViiV Healthca.

City ofUnited kingdomUnited statesNorth carolinaUnited kingdom generalKimberly smithKathleen quinnDan smithJosh williamsJeff mclaughlinSonya ghobrialMick readeyTim foleyJames dodwellMelinda stubbeeNick stone

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

Data reinforce ViiV Healthcare's leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention ViiV Healthcare, the global specialist HIV company majority-owned

United statesUnited kingdomNorth carolinaCity ofUnited kingdom generalKimberly smithKathleen quinnDan smithJosh williamsJeff mclaughlinSonya ghobrialMick readeyTim foleyJames dodwellKostenloser wertpapierhandelMelinda stubbee

vimarsana © 2020. All Rights Reserved.